David Pope Mackay, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 207 Meetinghouse Rd, Bedford, NH 03110 Phone: 603-668-2771 Fax: 603-627-3115 |
Dr. Nancy Eileen Wolf, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 39 South River Road, Bedford, NH 03110 Phone: 603-836-5353 Fax: 603-836-5356 |
Paul Edward Noury, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 73 S River Rd, Bedford, NH 03110 Phone: 603-668-5150 Fax: 603-668-5150 |
Family Eye Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 17 Colby Ct, Bedford, NH 03110 Phone: 603-623-0622 |
Koray Tolga Arin, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 17 Colby Ct, Bedford, NH 03110 Phone: 603-623-0622 |
Paul E Noury Od Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 73 So River Rd, Bedford, NH 03110 Phone: 603-668-5150 Fax: 603-668-5150 |
News Archive
At a recent donor conference in Brussels, Belgium, "the Global Fund to Fight AIDS, Tuberculosis and Malaria presented a compelling case for funding the organization to not only tackle these diseases but also to accelerate gains against them.
Single atom quantum dots created by researchers at Canada's National Institute for Nanotechnology and the University of Alberta make possible a new level of control over individual electrons, a development that suddenly brings quantum dot-based devices within reach.
A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at Duke Cancer Institute is part of an effective, two-drug strategy for enlisting the immune system to fight tumors, according to a Duke-led study in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Information about COVID-19 offered by the U.S. Centers for Disease Control and Prevention, the White House, and state health departments failed to meet recommendations for communicating with the public, according to a Dartmouth study.
QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain.
› Verified 6 days ago